
AI Gene Editing: Analyzing the Eli Lilly-Profluent Deal
Examine the $2.25B Eli Lilly-Profluent deal. Learn how generative AI and protein design are creating novel recombinases for kilobase-scale genome editing.

Examine the $2.25B Eli Lilly-Profluent deal. Learn how generative AI and protein design are creating novel recombinases for kilobase-scale genome editing.

Examine the 2026 landscape of AI biologics discovery. This analysis details protein modeling, generative design, and key pharma R&D investment trends.
© 2026 IntuitionLabs. All rights reserved.